Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@Trek, thanks - sounds like you've had a cracking run. I'm still in training but having fun here and at VAL.
Hi Hypermarlin,
Yes I don’t post there much now, or here unless an RNS as on an almost free carry at AVCT, SNG and 100% free carries here and at TXP, ORPH, GGP and NCYT (sold). Just working on one at ONC now in Pharma and a few gold miners for next year.
ATB to you and yours.
Trek
@Hello Trek, I remember you from AVCT! Hope all is well.
Are DDDD getting ready to join the big league?
IBS seems almost like a stepping stone off which we can aim for the (possible) major next stage project successes in oncology and, ultimately, neurodegeneration. The scale and importance of Part B oncology trial means 4d is not willing to leave anything to chance. Such hiring makes perfect sense on different fronts not least showing to the market and the sector that we mean business.
I think it’s here regulatory experience and knowledge that will be key from a NED perspective. Navigating new LBT tech through various approval stages and meeting all the compliance for MicroRX will require the experience of someone that has done it before. That sits well from a NED perspective.
I am also beginning to wonder if MSD are one the the mystery big Pharma Co’s working with ONC given the Keytruda links with their SeroTag platform. It’s just the timings of the part A and B trials with small cell cancers and cross validation with autoantibodies response; would make a lot of sense. Guess we’ll find out in time.
Atb
Trek
Lined up perfectly for news and further networking in the US pre Nasdaq listing ;-)
Based in New York.... Perfect for Nasdaq ;-)
It's all coming together....another RNS due anytime...don't want to be out of this for a minute.
A very high-powered appointment, bringing loads of experience (and contacts including China I note). I don't think she would be associating herself with 4d unless she was very confident about the quality of the company, management and prospects. This is great news.
Katrin Rupalla Current Workplace
Bristol-Myers Squibb Company Logo
Bristol-Myers Squibb Company
Location
430 E. 29th St., 14 th Fl.,
New York City, New York, 10016,
United States
Industry
Drug Manufacturing & Research, Pharmaceuticals, Healthcare, ...See More
Description
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or smal...
https://www.zoominfo.com/p/Katrin-Rupalla/1554681794
You wouldn't be appointing someone of that quality if you had poor results around the corner. Another piece of the jigsaw coming together.
Confidence is just oozing out of DDDD.
A really impressive addition to the board - here she is in action
https://www.youtube.com/watch?v=_hPnWsCFBb8
More encouraging news
sounds good!
RNS Number : 7898Z
4d Pharma PLC
23 September 2020
4D pharma plc
(the "Company" or "4D")
Directorate Change
4D pharma makes strategic appointment of independent Non-Executive Director in response to new clinical success and next stages of global development
Leeds, UK, 23 September, 2020 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Katrin Rupalla, Ph.D, as an independent Non-Executive Director with immediate effect.
Duncan Peyton, 4D's Chief Executive Officer, commented: "We are delighted to be able to attract someone of Katrin's calibre to our Board of Directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel Live Biotherapeutics into and through the clinic. With her background so well aligned with 4D's core focus areas of oncology and CNS, Katrin's experience and network across Europe, the US and China will support 4D's growth as we continue to expand our global profile."
Dr Rupalla brings to 4D pharma over twenty years of experience in the pharmaceutical industry, extensive regulatory and clinical expertise in the fields of oncology and neuroscience. Dr Rupalla has previously served in senior positions at Merck & Co., Roche, Celgene and Bristol-Myers Squibb (BMS). While at BMS, Dr Rupalla was Vice President Head R&D China and Global Development Team Leader for Opdivo/Yervoy in China, and then Vice President, Head Oncology Global Regulatory Sciences. Throughout her career, she has led regional and global teams responsible for obtaining approvals for multiple new therapeutics and indications, including Opdivo, Yervoy, Rituxan, Xeloda, Avastin, Revlimid and Vidaza, among others.
Dr Rupalla will make a considerable impact on 4D pharma's immediate and long-term clinical strategy across its Live Biotherapeutic development pipeline, including the application of the Rx platform and our earlier pre-clinical assets, but also our lead immuno-oncology candidate MRx0518 and neurodegenerative disease programs MRx0029 and MRx0005. Following the recent successful completion of the Part A safety phase of its ongoing trial of MRx0518 in combination with immune checkpoint inhibitor (ICI) Keytruda(R), which achieved a disease control rate (DCR) of 42% in heavily pre-treated patients refractory to prior ICI therapy, the Part B cohort expansion phase of the trial is currently enrolling at multiple sites as announced. Dr Rupalla will be a valuable new voice helping to guide and deliver the expanding global clinical development program for MRx0518.
Dr Rupalla currently serves as Senior Vice President, Global Head Regulatory Affairs, Medical Documentation and R&D Quality at Lundbeck, a leading biopharmaceutical developing novel therapeutics for diseases of the central nervous system (CNS).
Dr Rupalla has a Ph.D in CNS Pharmacology from the Philipps-University Marburg, Ger